Chemotherapy Associated Ovarian Failure

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2020 Dec 28

PMID 33363515

Citations 29

Authors

Davide Mauri

Ioanna Gazouli

Georgios Zarkavelis

Alexandra Papadaki

Leonidas Mavroeidis

Stefania Gkoura

Panagiotis Ntellas

Anna-Lea Amylidi

Lampriani Tsali

Eleftherios Kampletsas

Affiliations

Soon will be listed here.

Abstract

As the incidence of malignancies in young adults is increasing, fertility preservation in cancer survivors arises as a major concern. Especially among female cancer patients, pregnancy rates are estimated to be 40% lower compared to women of the same age. Nowadays oncologists are to be preoccupied not only with their patients' successful treatment, but also with the maintenance of the potential of the latter to conceive and obtain children. Chemotherapy associated ovarian failure (COF), refers to disruption of ovarian function both as an endocrine gland and as a reproductive organ, due to previous exposure to chemotherapy agents. Although the underlying mechanism is not fully understood, it is supposed that chemotherapy agents may induce either DNA damage of premature ovarian follicle or early activation and apoptosis of them, resulting into early exhaustion of available follicle deposit. Various chemotherapy agents have been associated with COF with the highest incidence being reported for patients undergoing combination regimens. Although a variety of alternatives in order to maintain ovarian function and fertility in female cancer survivors are available, adequately established practices to do so are lacking. Thus, it is of major importance to investigate further and collect sufficient evidence, aiming to guide patients and physicians in everyday clinical practice.

Citing Articles

miR-21-loaded bone marrow mesenchymal stem cell-derived exosomes inhibit pyroptosis by targeting MALT1 to repair chemotherapy-induced premature ovarian insufficiency.

Tang L, Yang Y, Yang M, Xie J, Zhuo A, Wu Y Cell Biol Toxicol. 2024; 41(1):3.

PMID: 39707056 PMC: 11662076. DOI: 10.1007/s10565-024-09946-6.

Exploring the innovative application of cerium oxide nanoparticles for addressing oxidative stress in ovarian tissue regeneration.

Lakshmanan M, Saini M, Nune M J Ovarian Res. 2024; 17(1):241.

PMID: 39633503 PMC: 11619646. DOI: 10.1186/s13048-024-01566-2.

MSCs-derived EVs protect against chemotherapy-induced ovarian toxicity: role of PI3K/AKT/mTOR axis.

Elsherbiny N, Abdel-Maksoud M, Prabahar K, Mohammedsaleh Z, Badr O, Dessouky A J Ovarian Res. 2024; 17(1):222.

PMID: 39529187 PMC: 11552115. DOI: 10.1186/s13048-024-01545-7.

Sexual health counseling improves the sexual satisfaction of breast cancer survivors: a randomized controlled trial.

Haghighi F, Bokaie M, Sefidkar R, Enjezab B Support Care Cancer. 2024; 32(11):768.

PMID: 39495310 DOI: 10.1007/s00520-024-08957-7.

Withanolide derivatives: natural compounds with anticancer potential offer low toxicity to fertility and ovarian follicles in mice.

Palomino G, Celiz H, Gomes F, Tetaping G, Novaes M, Rocha K Anim Reprod. 2024; 21(4):e20240027.

PMID: 39494127 PMC: 11529970. DOI: 10.1590/1984-3143-AR2024-0027.

References

Dolmans M, Lambertini M, Macklon K, Almeida Santos T, Ruiz-Casado A, Borini A . EUropean REcommendations for female FERtility preservation (EU-REFER): A joint collaboration between oncologists and fertility specialists. Crit Rev Oncol Hematol. 2019; 138:233-240. DOI: 10.1016/j.critrevonc.2019.03.010. View

Soleimani R, Heytens E, Darzynkiewicz Z, Oktay K . Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. Aging (Albany NY). 2011; 3(8):782-93. PMC: 3184979. DOI: 10.18632/aging.100363. View

Bar-Joseph H, Ben-Aharon I, Tzabari M, Tsarfaty G, Stemmer S, Shalgi R . In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels. PLoS One. 2011; 6(9):e23492. PMC: 3170286. DOI: 10.1371/journal.pone.0023492. View

Munhoz R, Pereira A, Sasse A, Hoff P, Traina T, Hudis C . Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2015; 2(1):65-73. PMC: 5003018. DOI: 10.1001/jamaoncol.2015.3251. View

Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S . Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011; 306(3):269-76. DOI: 10.1001/jama.2011.991. View

Pacheco F, Oktay K . Current Success and Efficiency of Autologous Ovarian Transplantation: A Meta-Analysis. Reprod Sci. 2017; 24(8):1111-1120. DOI: 10.1177/1933719117702251. View

Leonard R, Adamson D, Bertelli G, Mansi J, Yellowlees A, Dunlop J . GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol. 2017; 28(8):1811-1816. DOI: 10.1093/annonc/mdx184. View

Lee S, Schover L, Partridge A, Patrizio P, Wallace W, Hagerty K . American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006; 24(18):2917-31. DOI: 10.1200/JCO.2006.06.5888. View

Moore H, Unger J, Phillips K, Boyle F, Hitre E, Porter D . Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015; 372(10):923-32. PMC: 4405231. DOI: 10.1056/NEJMoa1413204. View

10.

Eichenauer D, Aleman B, Andre M, Federico M, Hutchings M, Illidge T . Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv19-iv29. DOI: 10.1093/annonc/mdy080. View

11.

Pereyra Pacheco B, Mendez Ribas J, Milone G, Fernandez I, KVICALA R, Mila T . Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol. 2001; 81(3):391-7. DOI: 10.1006/gyno.2001.6181. View

12.

Morita Y, Perez G, Paris F, Miranda S, Ehleiter D, Haimovitz-Friedman A . Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med. 2000; 6(10):1109-14. DOI: 10.1038/80442. View

13.

Peccatori F, Azim Jr H, Orecchia R, Hoekstra H, Pavlidis N, Kesic V . Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6:vi160-70. DOI: 10.1093/annonc/mdt199. View

14.

. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2012; 99(1):37-43. DOI: 10.1016/j.fertnstert.2012.09.028. View

15.

Demeestere I, Brice P, Peccatori F, Kentos A, Dupuis J, Zachee P . No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. J Clin Oncol. 2016; 34(22):2568-74. DOI: 10.1200/JCO.2015.65.8864. View

16.

Kawamura K, Cheng Y, Suzuki N, Deguchi M, Sato Y, Takae S . Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad Sci U S A. 2013; 110(43):17474-9. PMC: 3808580. DOI: 10.1073/pnas.1312830110. View

17.

Carmely A, Meirow D, Peretz A, Albeck M, Bartoov B, Sredni B . Protective effect of the immunomodulator AS101 against cyclophosphamide-induced testicular damage in mice. Hum Reprod. 2009; 24(6):1322-9. DOI: 10.1093/humrep/den481. View

18.

Skaznik-Wikiel M, McGuire M, Sukhwani M, Donohue J, Chu T, Krivak T . Granulocyte colony-stimulating factor with or without stem cell factor extends time to premature ovarian insufficiency in female mice treated with alkylating chemotherapy. Fertil Steril. 2013; 99(7):2045-54.e3. PMC: 3672312. DOI: 10.1016/j.fertnstert.2013.01.135. View

19.

Zhang Y, Xiao Z, Wang Y, Luo S, Li X, Li S . Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients. PLoS One. 2013; 8(11):e80444. PMC: 3842920. DOI: 10.1371/journal.pone.0080444. View

20.

Noyes N, Porcu E, Borini A . Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online. 2009; 18(6):769-76. DOI: 10.1016/s1472-6483(10)60025-9. View